News & Updates
Filter by Specialty:
Oral ritlecitinib safe, effective for treatment of active nonsegmental vitiligo
Treatment with oral ritlecitinib improves outcomes in patients with active nonsegmental vitiligo, without any serious adverse events over 48 weeks, results of a study have shown.
Oral ritlecitinib safe, effective for treatment of active nonsegmental vitiligo
27 Jan 2023
Add-on cannabidiol induces sustained seizure reduction in treatment-resistant epilepsy
Patients with treatment-resistant epilepsy appear to benefit from add-on cannabidiol, which a recent study has shown to help reduce seizure frequency for up to 192 weeks.
Add-on cannabidiol induces sustained seizure reduction in treatment-resistant epilepsy
27 Jan 2023
Solriamfetol reduces sleepiness in patients with OSA, narcolepsy
A recent study has shown the efficacy of solriamfetol as an alternative treatment for managing excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnoea (OSA).
Solriamfetol reduces sleepiness in patients with OSA, narcolepsy
24 Jan 2023
Some antihypertensive medications may lower dementia risk
Use of angiotensin II (ATII)-stimulating antihypertensive medication (AHM), angiotensin receptor blockers (ARBs), and dihydropyridine calcium channel blockers (CCBs) helps reduce the risk of dementia over a decade, but this beneficial effect decreases over time, according to a study.